United Kingdom
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • CH
    • DK
    • PL
  • News
  • UK
  • World
  • Business
  • Technology
  • Science
  • Entertainment
  • Sports
  • Health
  • @
  • Artificial intelligence
  • Arts and design
  • Birmingham
  • Books
  • Boxing
  • Brexit
  • Bristol
  • Britain
  • Business
  • Celebrities
  • Computing
  • Cricket
  • Cycling
  • Economy
  • Edinburgh
  • England
  • Entertainment
  • Entrepreneurship
  • Environment
  • EU
  • F1
  • Fitness
  • Football
  • France
  • Gadgets
  • Genetics
  • Germany
  • Glasgow
  • Golf
  • Health
  • Healthcare
  • Internet
  • Jobs
  • Leeds
  • Liverpool
  • London
  • Manchester
  • Markets
  • Medication
  • Mental health
  • Mobile
  • Movies
  • Music
  • News
  • Northern Ireland
  • Nutrition
  • Personal finance
  • Physics
  • Racing
  • Royals
  • Rugby
  • Russia
  • Science
  • Scotland
  • Sheffield
  • Space
  • Spain
  • Sports
  • Technology
  • Tennis
  • TV
  • UK
  • Ukraine
  • United Kingdom
  • United States
  • Virtual reality
  • Wales
  • Wildlife
  • World
United Kingdom
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • CH
    • DK
    • PL
  • News
  • UK
  • World
  • Business
  • Technology
  • Science
  • Entertainment
  • Sports
  • Health
  • @

Browsing Tag

statistical significance

3 posts
MMedication
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Read More

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

  • 1 July 2026
Moleculin Biotech, Inc. Moleculin Biotech, Inc. INTERIM EFFICACY – N=45 INTENT TO TREAT (ITT) Both Annamycin dose arms…
MMental health
Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
Read More

Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal

  • 29 July 2025
atai Life Sciences (ATAI) company Recognify Life Sciences has reported that its Phase IIb trial of oral compound,…
BBristol
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Read More

Bristol Myers’ Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

  • 23 April 2025
Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the…
United Kingdom
www.europesays.com